Dysregulation of the PI3K/Akt/mTOR signaling cascade has been associated with the pathology of neurodegenerative disorders, specifically Alzheimer's disease (AD). Both in-vivo models and post-mortem brain samples of individuals with AD have commonly shown hyperactivation of the pathway. In the present study, we examine how neuron subset-specific deletion of Pten (NS-Pten) in mice, which presents with hyperactive mammalian target of rapamycin (mTOR) activity, affects the hippocampal protein levels of key neuropathological hallmarks of AD. We found NS-Pten knockout (KO) mice to have elevated levels of amyloid-β, α-synuclein, neurofilament-L, and pGSK3α in the hippocampal synaptosome compared with NS-Pten wild type mice. In contrast, there was a decreased expression of amyloid precursor protein, tau, GSK3α, and GSK3β in NS-Pten KO hippocampi. Overall, there were significant alterations in levels of proteins associated with AD pathology in NS-Pten KO mice. This study provides novel insight into how altered mTOR signaling is linked to AD pathology, without the use of an in-vivo AD model that already displays neuropathological hallmarks of the disease. NeuroReport
Introduction
Cell signaling through the mammalian target of rapamycin (mTOR) pathway controls a multitude of cellular functions in the brain throughout the lifespan. The mTOR kinase is a master regulator of the survival, differentiation, and development of neurons, as well as regulation of several metabolic and autophagic processes [1] . In the adult brain, mTOR signaling is critical for synaptic plasticity, learning, and memory formation [1] . Given these prominent regulatory roles, previous studies have speculated that mTOR may be a promising target for attenuating pathologic neurodegeneration in the adult brain [2, 3] . Several neurodegenerative disorders, including Alzheimer's disease (AD), Huntington's disease, and Parkinson's disease, exhibit dysregulated mTOR activity and have impaired mTOR-dependent functions [4] .
AD is the leading cause of dementia in the elderly population, accounting for~60-80% of all dementia cases worldwide [5] . This disease is characterized by intracellular plaques formed by the amyloid-β (Aβ) peptide and extracellular neurofibrillary tangles (NFTs) comprised of hyperphosphorylated tau [6] . Evidence has shown Aβ accumulation to have a prominent role in AD pathology, initiating a deleterious cascade resulting in cognitive impairment. Among the host of growth factors, nutrients, and stress signals that traditionally stimulate mTOR signaling, Aβ has also been shown to activate this pathway [7] .
In both in-vivo models of AD and in post-mortem brain samples of individuals with the disease, numerous studies have showed mTOR hyperactivation [8] [9] [10] . This hyperactivation has been found to be, in part, mediated by the accumulated Aβ in diseased neural tissue [11] . One critical regulator of Aβ clearance and degradation is the induction of autophagy, which is negatively controlled by mTOR activity. Thus, autophagic processes are often dysregulated in AD mouse models and in individuals with AD [12] . This concomitant enhancement of Aβ aggregation and decreased Aβ clearance seems to create a positive feedback loop, fostering net growth of plaques and mTOR hyperactivation. mTOR signaling also plays a role in tau aggregation and degradation, and pathway activity can increase the translation of tau protein [4, 10] . Considerable evidence has linked mTOR hyperactivation with AD-associated pathology; however, the exact mechanism linking Aβ plaques, Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.neuroreport.com.
NFTs, and cognitive decline in the brains of individuals with AD remains elusive.
Phosphatase and tensin homolog located on chromosome 10 (PTEN) functions to inhibit the mTOR pathway and may play a critical role in regulating AD pathology. This protein negatively regulates PI3K/Akt/mTOR signaling by removing a phosphate group from phosphatidylinositol (3,4,5)-trisphosphate, converting it to phosphatidylinositol (3,4,5)-bisphosphate. PTEN has well established roles in neurodevelopment, as loss of PTEN function results in hyperconnectivity, excessive brain growth, and cognitive impairments [13] . There is also a growing body of evidence that PTEN contributes to a number of normal brain functions, including synaptic transmission, plasticity, neurogenesis, neurite outgrowth, and longterm depression [14] . Knafo and colleagues found that PTEN functions downstream of the action of Aβ, and that the PDZ-binding domain of PTEN is essential to the AD-associated synaptic dysfunction observed in the disease. Furthermore, they found that inhibiting PTEN rescued normal synaptic function and cognitive impairments in both in-vitro and in-vivo models of AD [15] .
The present study will examine how neuron subsetspecific deletion of the Pten gene (NS-Pten) in mice can result in alterations in the level of proteins associated with AD. We will examine the expression of Aβ, tau, amyloid precursor protein (APP), α-synuclein, neurofilament-L, phospho-GSK3α (pGSK3α), GSK3α, and GSK3β. These findings enhance our understanding of how hyperactive mTOR signaling, without the presence of AD pathology in an in-vivo AD model, can be associated with protein alterations characteristic of AD pathology.
Methods

Animals
Experimental mice included adult (8 weeks old) neuron subset-specific Pten (NS-Pten) conditional knockout (KO) (n = 9) and wild type (WT) (n = 9) mice, previously described as GFAP-Cre; Pten l°xP/loxP mice [16, 17] . This conditional KO model exhibits Cre activity primarily in hippocampal granule neurons of the dentate gyrus that express NeuN, with activity rarely observed in glial cells immunopositive for S100β or GFAP [16] . NS-Pten loxP/ + heterozygote parents were bred over 10 generations on a FVB-based backcrossed strain to produce NS-Pten 
Western blotting analysis
Adult NS-Pten KO and WT mice were euthanized at 8 weeks of age and brains were rapidly dissected, rinsed in 1 × PBS on ice, and the hippocampus removed before being placed on dry ice and stored at − 80°C. Whole hippocampus samples from the right hemisphere were homogenized in ice-cold homogenization buffer containing 0.32 M sucrose, 1 mM EDTA, 5 mM HEPES, and a protease inhibitor cocktail (Sigma, St. Louis, Missouri, USA) and processed for western blotting as previously described [18] . Crude synaptosomes of all samples were run through 8-12% SDS-PAGE gels, followed by being transferred overnight to Hybond-P polyvinyl difluoride membranes (GE Healthcare, Piscataway, New Jersey, USA). Membranes were incubated for 1 h at room temperature in a blocking solution consisting of 5% nonfat milk diluted in 1 × Tris-buffered saline (50 mM Tris-HCl, pH = 7.4, 150 mM NaCl) with 0.1% Tween (1 × TTBS) and 1 mM Na 3 VO 4 . The membranes were then incubated overnight at 4°C on a Hoeffer rocker II with the following primary antibodies in 5% milk in TTBS: α-synuclein, Aβ, neurofilament-L, phospho-GSK3α, GSK3α, GSK3β, APP, and tau (see Table S1 , Supplemental digital content 1, http://links.lww. com/WNR/A473, for antibody specifics). Following the incubation period, membranes were washed in 1 × TTBS (3 × 5 min), and then incubated with horseradish peroxidase-labeled secondary antibodies in a milk solution (1 : 20 000) for 1 h. Secondary antibodies were antirabbit immunoglobulin G or anti-mouse IgG (Cell Signaling Technology, Boston, Massachusetts, USA). Following another set of washes in 1 × TTBS (3 × 5 min), membranes were incubated in ECL Prime (GE Healthcare, Piscataway, New Jersey, USA) for 5 min at room temperature and immunoreactive bands were imaged with a digital western blot imaging system (ProteinSimple, Santa Jose, California, USA). The optical density of immunoreactive bands was measured using ProteinSimple AlphaView software (ProteinSimple, San Jose, California, USA). Measurements from all protein bands of interest were normalized to endogenous actin or mortalin levels for each tissue sample and all groups were normalized to the control group average per blot. All experimental data points represent a single tissue sample (n = 1).
Statistical analysis
Data were analyzed using GraphPad Prism 7 software (Graphpad Software Inc., San Diego, California, USA) or SPSS 25.0 (IBM, USA). Independent samples t-tests were utilized for western blot analyses between NS-Pten KO and WT mice. In cases in which the homogeneity of variance assumption was violated, nonparametric Mann-Whitney U-tests were carried out. For all analyses a value of P less than 0.05 was considered significant. Data are expressed as mean SEM or median IQR (interquartile range).
Results
The present study examined the influence of neuron subset-specific deletion of Pten (NS-Pten) on proteins associated with AD pathology and found significant alterations in NS-Pten KO mice hippocampal synaptosome protein levels compared with WT mice. NS-Pten KO mice had significantly elevated Aβ (U = 7, P < 0.01), neurofilament-L [t(1,16) = 3.24, P < 0.01], α-synuclein [t(1,16) = 2.12, P = 0.05], and % total pGSK3α (U = 4, P = 0.001). In contrast, NS-Pten KO mice had significantly decreased APP (U = 15, P < 0.05), GSK3α (U = 9, P < 0.01), GSK3β [t(1,16) = 3.99, P = 0.001], and tau [t(1,16) = 3.49, P ≤ 0.01] hippocampal protein levels compared with WT mice (Fig. 1) .
Discussion
This study found significant alterations in proteins associated with AD pathology in NS-Pten KO mice compared with NS-Pten WT mice. Specifically, we found elevated levels of Aβ, α-synuclein, neurofilament-L, and pGSK3α protein expressions in the hippocampal synaptosome of NS-Pten KO mice. We also detected decreased APP, tau, GSK3α, and GSK3β in NS-Pten KO hippocampi. PTEN functions to negatively regulate the PI3K/Akt/mTOR pathway, and therefore, deletion of this inhibitory protein results in enhanced mTOR signaling. These results corroborate other studies that have shown hyperactivation of the mTOR pathway to be associated with AD pathology. Furthermore, this study provides novel insight into how mTOR is associated with AD pathology without the presence of already developed hallmarks of the disease, such as Aβ accumulation and NFTs, as seen in many in-vivo AD models.
Previous evidence suggests that Aβ is primarily responsible for the hyperactivation of mTOR observed in both the brains of individuals with AD and in AD rodent models [4, 11] . Specifically, Aβ is thought to interact with mTOR signaling through the inhibitory protein prolinerich Akt substrate of 40 kDa (PRAS40), a component of the mTORC1 complex [19] . Aβ directly phosphorylates PRAS40, thus removing its inhibitory effect on mTOR and upregulating pathway activity [11] . Interestingly, we found Aβ to be significantly elevated in the hippocampus of NS-Pten KO mice, suggesting that Aβ could potentially Fig. 1 Deletion of Pten results in altered hippocampal synaptosome protein levels associated with Alzheimer's disease pathology. NS-Pten knockout (KO) mice (n = 9) had increased expressions of amyloid-β (Aβ) (a), neurofilament-L (b), α-synuclein (c), % total pGSK3α (d) compared to NS-Pten WT mice (n = 9). In contrast, NS-Pten KO mice had significantly reduced expression of APP (e) tau (f), GSK3α (g), and GSK3β (h). Data are expressed as mean SEM for neurofilament-L, α-synuclein, tau, and GSK3β. Data are expressed as median interquartile range for Aβ, % total pGSK3α, APP, and GSK3α. *P < 0.05.
NS-Pten
be involved in a positive feedback loop contributing to further hyperactivation of the pathway beyond the effect of Pten deletion.
In addition to the accumulation of Aβ, the mTOR pathway and specifically, PTEN activity, has been linked to tau pathology in AD [8] . Under normal physiological conditions, tau functions as a microtubule-associated protein to promote the assembly of microtubule binding in neurons [20] . However, when hyperphosphorylated, it dissociates from cytoskeletal elements and accumulates, contributing to NFT development [20] . Hyperactivation of the mTOR pathway, whether independently or directly related to Aβ accumulation, has been linked to major features of tau pathology, including tau translation, degradation, aggregation, hyperphosphorylation, and development of NFTs [3] . Furthermore, mTOR activity can increase the translation of tau mRNA by p70S6K activation, and p70S6K can co-localize with hyperphosphorylated tau, thus promoting tau accumulation in AD [2, 21] . In contrast to this evidence, the present study found decreased tau protein levels in the hippocampal synaptosomes of NS-Pten KO mice compared with controls, suggesting that mTOR activity can both promote and protect against tau deposition in the brains of those with AD.
The relationship between PTEN, mTOR signaling, and glycogen synthase kinase 3 (GSK3) is thought to play a pivotal role in the regulation of tau phosphorylation and hyperphosphorylation. PTEN's inhibitory activity on Akt by PDK1 results in increased GSK3 activation, in which GSK3 can phosphorylate tau at multiple sites in-vivo and in-vitro promoting development of tau pathology [20, 22] . Thus, it could be predicted that deletion of PTEN leads to downregulation of GSK3, and subsequently reduced tau hyperphosphorylation, coinciding with our findings in the NS-Pten KO mouse. However, we found increased phospho-GSK3β, but downregulated GSK3α and GSK3β, which could explain some of the unexpected findings in tau levels. Increased levels of phospho-Akt substrates, such as phospho-GSK3, have been observed in temporal cortex neurons in humans with AD, which does corroborate our findings of elevated phospho-GSK3α in the NS-Pten KO mouse [23] . It is important to note that our study examined proteins in the hippocampal synaptosomal subcellular compartment, while other studies have used total homogenate preparations of tissue from postmortem AD brains or transfected primary neuronal cultures which could account for discrepancies between studies [21, 22] .
The significant impact that neuronal deletion of Pten had on components of AD pathology supports previous evidence suggesting that mTOR inhibitors could be a potential avenue for treatment of the disease. Studies have shown that the mTOR inhibitor, rapamycin, can prevent memory deficits and reduce Aβ and tau pathology in in-vivo AD models [24, 25] . These findings could be attributed to a multitude of mechanisms, most likely by anti-aging effects such as enhancing autophagy function and decreasing protein translation [8, 9, 24, 25] . However, dramatically reducing mTOR activity could also negatively affect cognition, as normal mTOR activity is critical for learning and memory formation [5] . It is essential to continue investigating alternative mechanisms of modulating mTOR, fine-tuning the pathway for optimal cellular regulation, and cognitive function.
Conclusion
These results highlight the critical role that the mTOR pathway plays in regulating Aβ and tau pathologies, as well as other proteins associated with AD.
